TransMedics Group (TMDX) to Release Quarterly Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) is projected to announce its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $155.2790 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

TransMedics Group Stock Up 1.0%

TMDX opened at $129.84 on Tuesday. TransMedics Group has a one year low of $62.07 and a one year high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The stock has a market capitalization of $4.44 billion, a P/E ratio of 52.57 and a beta of 2.06. The business’s 50-day simple moving average is $132.18 and its 200-day simple moving average is $125.62.

Insider Activity

In related news, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares in the company, valued at $2,103,235.68. This trade represents a 5.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider owned 13,955 shares in the company, valued at $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 8,920 shares of company stock worth $1,257,310 in the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of TransMedics Group

Institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC raised its stake in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the last quarter. Canada Pension Plan Investment Board raised its position in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after acquiring an additional 100 shares during the last quarter. US Bancorp DE lifted its holdings in shares of TransMedics Group by 24.2% in the third quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after purchasing an additional 104 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after purchasing an additional 108 shares during the last quarter. Finally, Allworth Financial LP increased its stake in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TMDX shares. Needham & Company LLC increased their price objective on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Finally, Morgan Stanley lifted their target price on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.